Topic- Hemophagocytic Lymphohistiocytosis: A New Foe
Volume 1 - Issue 2
Rohit Vohra1* and Dr Minakshi2
-
Author Information
Open or Close
- 1Department of Pediatric emergency and critical care medicine, Sir Ganga Ram Hospital, India
- 2Department of Pediatric Hematology and Oncology, Sir Ganga Ram Hospital, India
*Corresponding author:
Rohit Vohra, Department of Pediatric emergency and critical care medicine, Sir Ganga Ram Hospital, New Delhi,
India
Received: February 05, 2018; Published: February 16, 2018
DOI: 10.32474/PAPN.2018.01.000108
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. It
commonly affects infants from birth to 18 months of age, but the disease can be seen in children and adults of all ages. HLH can occur as
a familial or sporadic disorder, and it can be triggered by a variety of events that disrupt immune homeostasis. Prompt recognition of the
disease and initiation of treatment is essential for the survival of affected patients [1]..
Keywords: HLH; NK cells; Immune system
Abbrevations: HLH: Hemophagocytic lymphohistiocytosis; NK: Natural killer; CTLs: cytotoxic T- lymphocytes
Abstract|
Introduction|
Diagnosis|
Treatment|
References|